Abstract: Pulmonary embolism and deep venous thrombosis constitute a major cause of vascular illness in the USA. The mortality rate of pulmonary embolism is high, and recurrent events frequently occur. The optimal duration of treatment with anticoagulation is unknown. Diagnostic work-ups now often include plasma D-dimer levels and echocardiography in addition to conventional lung scanning and pulmonary angiography. Among patients with right ventricular dysfunction, thrombolytic therapy is being used more often because this strategy may improve overall prognosis. Since venous thromboembolism is difficult to diagnose and expensive to treat, prophylaxis against this disease is of paramount importance.
Introduction
More than 250 000 patients are hospitalized annually in the USA with pulmonary embolism (PE) or deep venous thrombosis (DVT), and one-third suffer recurrent episodes. PE has a high mortality rate. In a registry of 2454 patients spanning seven countries and 52 hospitals, ICOPER (the International Cooperative Pulmonary Embolism Registry) reported that the 3-month mortality rate was 17.5%. 1 PE was the principal cause of death. Both PE and DVT have high recurrence rates after anticoagulation is discontinued. A Scandinavian study found that after 6 months of anticoagulation, PE patients have a 13% likelihood of recurrence within the following 2 years. 2 In a DVT registry that followed patients for 8 years after cessation of anticoagulation, 30% suffered recurrent venous thrombosis and 29% developed venous insufficiency of the legs. 3 Venous thromboembolism encompasses both PE and DVT, which are manifestations of the same disease. When thrombi form in the deep veins of the legs, pelvis, or upper extremities, they may embolize to the pulmonary arteries and elevate pulmonary vascular resistance. Consequently, right ventricular afterload and wall tension increase, at times causing right heart failure and cardiogenic shock. Simultaneously, increased alveolar dead space and reflex bronchoconstriction may impair gas exchange.
The Nurses' Health Study has identified three controllable risk factors for PE: obesity, cigarette smoking, and systemic arterial hypertension. 4 Concomitant conditions that predispose to PE include surgery or trauma, cancer and hormonal influences such as oral contraceptives, 5-7 pregnancy and hormonal replacement therapy.
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Of various identified thrombophilias, the factor V Leiden mutation is most often associated with venous thrombosis.
Less common are hyperhomocysteinemia, 12 lupus anticoagulant 13 and deficiencies of antithrombin III, protein C and protein S. 14 A combination of disorders elevates the risk of venous thromboembolism (VTE). 15 For example, in the Physicians' Health Study, 16 combined hyperhomocysteinemia and factor V Leiden increased the risk of any venous thrombosis by almost tenfold and of idiopathic venous thrombosis by a factor of 20.
Diagnosis
The differential diagnosis of PE is extensive (Table 1) . Physical findings of right heart failure may include: bulging neck veins with v waves, a left parasternal lift, an accentuated pulmonic component of the second heart sound and a systolic murmur at the left lower sternal border that increases in intensity during inspiration.
The most frequent electrocardiographic abnormality is T wave inversion in the anterior chest leads, V1-V4. 17 New onset right bundle branch block or atrial fibrillation is far less common. The chest X-ray is often normal.
Hypoxemia or an increased alveolar-arterial oxygen gradient calculated from arterial blood gases cannot accurately discriminate between those patients suspected of PE who require further investigation and those in whom no further work-up is required. 18, 19 However, a normal plasma D-dimer enzyme-linked immunosorbent assay (ELISA) excludes PE with about 90% certainty. Unfortunately, the D-dimer ELISA lacks specificity and is elevated in the presence of myocardial infarction, pneumonia, heart failure, cancer and following surgery. Therefore, it is best used to exclude PE among patients with low clinical suspicion who present to the emergency department or office without other systemic illness. 20, 21 Because PE and DVT are part of the same pathological process, abnormal imaging tests are often found in both the deep leg veins and the lungs. For example, among DVT patients without symptoms of PE, nearly 40% had evidence of PE on lung scanning. 22 However, a normal leg imaging test cannot exclude PE. In a separate study of PE patients, only 43% had positive venous leg ultrasounds. 23 Unfortunately, the high probability lung scan is insensitive and identifies fewer than half of patients with PE. 24 Furthermore, in the presence of high clinical suspicion for PE, the 'low probability' lung scan is a potentially lethal reading, 25 which is more accurately categorized as 'nondiagnostic'. 26 Spiral chest CT scanning with contrast is best suited for identifying PE in the proximal pulmonary arteries. 27 Magnetic resonance pulmonary angiography 28 can display the anatomy of the pulmonary arteries as well as assess right ventricular wall motion.
Transthoracic echocardiography is particularly useful in critically ill patients with suspected PE. 29 Often, echocardiography can help identify conditions which mimic PE such as myocardial infarction, dissection of the aorta, or pericardial tamponade. The McConnell Sign demonstrates regional right ventricular dysfunction and appears to be specific for PE. Right ventricular apical wall motion remains normal despite hypokinesis of the right ventricular free wall. A 'hinge point' is observed at the border of the mid apical free wall and the apex. 30 Detection of right ventricular hypertrophy suggests that the process is chronic, subacute, or acute superimposed upon chronic.
Contrast pulmonary angiography remains the gold standard. When performed by experienced staff, it is usually safe. 31 The pulmonary angiogram is especially useful when there is high clinical suspicion for PE despite non-diagnostic lung scanning, normal venous ultrasonography and normal echocardiography.
Therapy
Patients suspected of PE should be anticoagulated with heparin during the diagnostic work-up. A bolus (average 7500 IUnits) followed by a continuous infusion of unfractionated heparin (average 1250 IU/h), usually achieves rapidly a therapeutic activated partial thromboplastin time (PTT) that is at least twice the upper limit of normal. Heparin nomograms facilitate proper dosing. 32 Heparin alone is used during pregnancy to manage PE. 33 Heparin is also usually required in Trousseau's syndrome, because oral anticoagulation often fails to prevent recurrent thrombosis. 34 Although inpatient administration of low molecular weight heparin has been shown to be as safe and effective as unfractionated heparin to treat hemodynamically stable PE in two large trials, 35, 36 patients who received low-molVascular Medicine 1998; 3: [35] [36] [37] [38] [39] [40] ecular-weight heparin were hospitalized on average for 1 week. However, for treatment of DVT, otherwise healthy patients may be safely and effectively managed either as outpatients or with a hospital stay of several days as long as a comprehensive nurse-physician monitoring system is available to ensure detailed, meticulous follow-up. 37, 38 It is important to emphasize that treatment of DVT with lowmolecular-weight heparin is not FDA approved. Furthermore, it is unclear whether the results obtained in clinical trials with outpatient administration of low molecular weight heparin can be replicated in everyday clinical practice.
Warfarin can be started safely immediately after achieving a therapeutic PTT. Loading warfarin does not usually shorten the 5 days needed to obtain adequate oral anticoagulation; an initial average dose of 5 mg usually suffices. 39 The target international normalized ratio (INR) for warfarin is 2.0-3.0.
After a first episode of PE or DVT, 6 months of anticoagulation prevents far more recurrences than 6 weeks. 2 Indefinite anticoagulation after recurrent venous thrombosis will reduce the likelihood of further venous thromboembolism (VTE) at a cost of increasing the risk of major hemorrhage. 40 Whether patients with recurrent PE or those with factor V Leiden and an initial PE should receive prolonged courses of anticoagulation remains sharply debated; a definitive answer to optimal management of recurrent VTE will be obtained in the new NIH sponsored study called PREVENT.
Inferior vena caval (IVC) filters are indicated for PE patients who present with active hemorrhage or recurrent PE despite intensive and prolonged anticoagulation. However, filters do not halt the thrombotic process and may cause massive leg edema due to caval thrombosis. In a randomized controlled trial of 400 DVT patients without bleeding problems, IVC filters plus anticoagulation did not reduce mortality compared with anticoagulation alone. 41 Furthermore, filters appear to offer no advantage compared with anticoagulation alone in patients with free-floating proximal leg DVT.
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Pulmonary embolism thrombolysis
Urokinase was compared with heparin alone in 160 patients with angiographically documented PE in the Urokinase Pulmonary Embolism Trial. 43 The loading dose was 4400 IU/kg followed by 4400 IU/kg per h for 24 h. Urokinase dissolved pulmonary arterial clot more rapidly than heparin alone and, in certain instances, reversed clinical shock. However, there was no difference in the rate of death or recurrent PE between the two groups. Furthermore, hemorrhaghic complications occurred more often among those patients randomized to urokinase. In the UrokinaseStreptokinase PE Trial, 44 167 patients with angiographically documented PE were randomized to one of three different thrombolytic treatments: 12 h of urokinase, 24 h of urokinase, or 24 h of streptokinase. There was no heparin control group. When the three thrombolytic regimens were compared, morbidity and mortality were similar, as was the frequency of major bleeding complications. In a small PE trial of streptokinase 1 500 000 IU/h plus heparin versus heparin alone, streptokinase proved lifesaving in patients who presented with massive PE, hypotension and heart failure. 45 Among 101 'hemodynamically stable' PE patients randomized to recombinant human tissue-type plasminogen activator (rt-PA) 100 mg/2 h followed by heparin versus heparin alone, rt-PA provided striking improvement in right ventricular function and pulmonary perfusion. 46 Most importantly, no clinical episodes of recurrent PE occurred among rt-PA patients. However, five (two fatal and three non-fatal) clinically suspected recurrent PEs occurred within 14 days in patients randomized to heparin alone (p = 0.06), despite adequate anticoagulation as judged by partial thromboplastin times. All five presented initially with right ventricular hypokinesis on echocardiogram, despite normal systemic arterial pressure at baseline. Thus, echocardiography helped identify a subgroup of PE patients with impending right ventricular failure who appeared to be at high risk of adverse clinical outcomes if treated with heparin alone.
Evidence now exists from four PE registries that right ventricular failure (usually detected on echocardiogram) is associated with a poor prognosis, even with a normal systemic arterial pressure.
1,47- 49 The German Management And Prognosis of Pulmonary Embolism Registry (MAPPET) found that thrombolysis improved the clinical outcome of hemodynamically stable patients with major PE 50 ( Table  2) , despite a threefold higher rate of major bleeding.
The most feared complication of PE thrombolysis is intracranial hemorrhage. In a separate registry of 312 patients receiving thrombolysis for PE in five clinical trials, there was a 1.9% risk (95% CI, 0.7-4.1%) of intracranial bleeding. 50 Two of the six patients had pre-existing known intracranial disease and received thrombolysis in violation of the protocol. Diastolic blood pressure on admission was significantly elevated in patients who developed intracranial hemorrhage compared with those who did not (90.3 versus 77.6 mmHg; p = 0.04). These data indicate that meticulous patient screening for a history of uncontrolled hypertension, seizure disorders and other intracranial disease is imperative before administering for thrombolysis. Other risk factors associated with major bleeding after thrombolysis include increasing age and increasing body mass index. 51 Importantly, the time window for PE thrombolysis is quite wide: 14 days. 52 In addition, practical steps can be taken to streamline PE thrombolysis, thus making this process more efficient, economical and safer (Table 3) . For example, costs can be controlled by omitting testing of fibrinogen, fibrin(ogen) split products and thrombin time, all of which are generally unnecessary for clinical management. 53 If aggressive intervention is warranted in the setting 54 or open surgical embolectomy 55 should be considered.
DVT thrombolysis
DVT thrombolysis has been plagued by several vexing problems. First, clot dissolution with peripherally administered lytics is usually accomplished successfully in only one-third to two-thirds of individuals. 56 Secondly, associated comorbid conditions and a lengthy thrombolytic infusion period of 24 h or more predispose DVT patients to extensive hemorrhagic complications. Thirdly, even when thrombolysis is effectively achieved, successful clot lysis has not been demonstrated definitively to yield a reduction in clinically important adverse events. Fourthly, the population of DVT patients that is eligible for thrombolysis is quite narrow and, therefore, any thrombolytic strategy will apply at most to a small proportion of all DVT patients. 57, 58 Finally, thrombolysis almost always will extend the length of hospital stay for a DVT patient. No strategy for outpatient administration of DVT thrombolysis has yet been validated. In contrast, most evolving DVT treatment strategies rely upon an abbreviated hospital stay or a completely outpatient approach to DVT management. Thus, utilization of DVT thrombolysis will be severely restricted unless it is proven to have superior efficacy and equivalent safety and cost when compared with low-molecular-weight heparin given as a 'bridge' to warfarin.
The only FDA-approved dosing regimen for DVT thrombolysis is streptokinase 250 000 IU as a loading dose, followed by 100 000 IU/h for 24-72 h. No catheter-directed thrombolytic regimen has ever received FDA approval. Adverse clinical events such as intracranial hemorrhage require that perspectives are adjusted for DVT thrombolysis. DVT is simply not as life-threatening a condition as myocardial infarction of PE. Therefore, patients selected for DVT thrombolysis should be at lower risk for hemorrhagic complications than the overall population of myocardial infarction or PE patients who receive thrombolytic therapy.
Peripherally administered thrombolytic therapy works best in the presence of non-obstructive thrombi. 59, 60 Collateral venous flow around obstructive venous thrombi may prevent systemically administered fibrinolytic agents from reaching the thrombus in sufficient amounts to cause lysis. In such patients, catheter-directed DVT thrombolysis is much more effective than a peripherally administered drug. In practice, DVT thrombolysis is administered for massive thrombosis associated with threatened arterial insufficiency. DVT thrombolysis is also usually offered to young patients with iliofemoral venous thrombosis in an attempt to prevent or at least reduce the magnitude of subsequent venous insufficiency.
Prevention
Most hospitalized patients at moderate or high risk should receive mechanical or pharmacological prophylaxis against VTE. Mechanical methods include graduated compression stockings (GCS), intermittent pneumatic compression (IPC) devices, or IVC filters. Foot pumps are also available but have not been extensively investigated.
Pharmacologic prophylaxis includes fixed low-dose subcutaneous unfractionated heparin ('miniheparin'), low-molecular-weight heparin and warfarin. Miniheparin reduces the perioperative rate of fatal PE by two-thirds. 61 The typical dose is 5000 units, twice or three times daily, initially administered 2 h before the skin incision. Low-molecularweight heparins have superior bioavailability, require less frequent injections and have reduced rates of heparininduced thrombocytopenia compared with miniheparin. 62 Currently, three -enoxaparin, dalteparin and ardeparinand one heparinoid, danaparoid, 63 have received FDA approval for specific prophylaxis indications (Table 4) . 
